Adagrasib
A targeted oral therapy designed to block a specific mutated protein called KRAS G12C, which drives uncontrolled cell growth in certain cancers when mutated. It is used in adults with KRAS G12C-mutated non-small cell lung cancer and certain colorectal cancers that have progressed after prior treatment. Patients' tumors must be tested for the specific KRAS G12C mutation before starting treatment to confirm likely benefit.
Masse moléculaire
604,1000 g/mol
LogP
5,00
TPSA
88,80 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Selectively and irreversibly inhibits KRAS G12C, a mutant oncoprotein that drives uncontrolled cell proliferation in a subset of cancers. By locking KRAS in its inactive GDP-bound state, it blocks downstream RAS/MAPK signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively and irreversibly inhibits KRAS G12C, a mutant oncoprotein that drives uncontrolled cell proliferation in a subset of cancers. By locking KRAS in its inactive GDP-bound state, it blocks downstream …
Structure 2D
Cite this structure
Embed this structure
SMILES
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
InChI
InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
Molecular Formula
C32H35ClFN7O2
HBD / HBA
- / 9
Liaisons Rotatives
7
Atomes Lourds
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A targeted oral therapy designed to block a specific mutated protein called KRAS G12C, which drives uncontrolled cell growth in certain cancers when mutated. It is used in adults with KRAS G12C-mutated non-small cell lung cancer and certain colorectal cancers that have progressed after prior treatment. Patients' tumors must be tested for the specific KRAS G12C mutation before starting treatment to confirm likely benefit.
Selectively and irreversibly inhibits KRAS G12C, a mutant oncoprotein that drives uncontrolled cell proliferation in a subset of cancers. By locking KRAS in its inactive GDP-bound state, it blocks downstream RAS/MAPK signaling.
Yes, Adagrasib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594350. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 138611145. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="adagrasib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/adagrasib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/adagrasib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/adagrasib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="adagrasib"></drugfyi-drug>